StockNews.AI
EW
StockNews.AI
89 days

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

1. New study shows early intervention for severe AS lowers healthcare costs. 2. Prompt treatment reduces patient hospitalization by 2.2 days on average. 3. Delaying treatment increases one-year mortality risk significantly. 4. Edwards' findings emphasize timely care, reducing overall healthcare system burden. 5. CEO stresses importance of Heart Valve Team for early AS management.

6m saved
Insight
Article

FAQ

Why Bullish?

The positive clinical evidence supports a stronger position for Edwards in the heart valve market, similar to past successes seen after favorable trial results such as TAVR advances, demonstrating improved patient outcomes and cost savings could lead to increased adoption of Edwards' technologies, driving revenue growth.

How important is it?

The article's focus on economic and clinical advantages of early intervention highlights a competitive edge for Edwards, potentially influencing investor confidence and market position, reflected in the increased relevance score.

Why Long Term?

The emerging paradigm shift towards early intervention can lead to sustained increased demand for Edwards’ products, similar to long-term trends seen in valve replacement adoption rates following prior ground-breaking studies.

Related Companies

MDTSYKBSX
- PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatment (2.2 fewer days); and Fewer follow-up heart failure hospitalizations 1 year after treatment (80 percent less). Additionally, compared with asymptomatic severe AS, delaying treatment until the disease progressed resulted in a more than seven times higher rate of death within one year after aortic valve replacement (AVR). “We are dedicated to advancing robust evidence to help improve outcomes for patients with severe aortic stenosis,” said Larry Wood, Edwards’ corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. “These latest findings underscore the importance of early referral to a Heart Valve Team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.” Along with prior data from the EARLY TAVR trial, these results reinforce the value of early referral and evaluation by a Heart Valve Team for all patients with severe AS. “We continue to believe that watchful waiting is not an effective strategy for the management of severe AS,” said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. “The latest findings highlight the significant clinical and economic advantages of timely referral and treatment for severe AS patients.” About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by Mr. Wood and statements regarding expected benefits of prompt intervention before symptoms develop, patient benefits and outcomes, reduction in economic and resource burdens for the healthcare system and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com. Edwards, Edwards Lifesciences, the stylized E logo, and EARLY TAVR are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. More News From Edwards Lifesciences Corporation

Related News